Evonik Industries AG (ETR: EVK)
Market Cap | 7.66B |
Revenue (ttm) | 15.16B |
Net Income (ttm) | 228.00M |
Shares Out | 466.00M |
EPS (ttm) | 0.49 |
PE Ratio | 33.37 |
Forward PE | 11.60 |
Dividend | 1.17 (7.12%) |
Ex-Dividend Date | n/a |
Volume | 1,712,398 |
Open | 16.29 |
Previous Close | 16.39 |
Day's Range | 16.13 - 16.45 |
52-Week Range | 16.13 - 21.27 |
Beta | 1.03 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 5, 2025 |
About Evonik Industries AG
Evonik Industries AG produces specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure segments. The Specialty Additives segment provides additives for polyurethane; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-p... [Read more]
Financial Performance
Financial StatementsNews
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven can...
EQS-News: Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery
EQS-News: leon-nanodrugs GmbH / Key word(s): Study results Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery 05.12....
Evonik: A Good Company, Upside Less Clear Than Before
EQS-DD: Evonik Industries AG: Dr. Cornelius Baur, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 26.11.2024 / 10:25 CET/CEST The issuer is solely responsi...
Evonik opens new Care Solutions Innovation lab in Thane
Evonik Industries AG (EVKIF) Q3 2024 Earnings Call Transcript
Evonik Industries AG 2024 Q3 - Results - Earnings Call Presentation
Evonik Industries reports Q3 results
Agilis Unveils 'Alchemist' AI Solutions to Transform Customer Engagement in the Chemical Industry, with Evonik as Pilot Customer
Newark, New Jersey--(Newsfile Corp. - September 17, 2024) - Agilis, a leader in digital customer engagement solutions for the chemical industry, today announces the launch of Alchemist, a suite of AI-...
Early Warning Press Release of Evonik Venture Capital GmbH
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - Evonik Venture Capital GmbH ("Evonik"), an entity controlled by Evonik Industries AG, a publicly-listed German company, holds 10,00...
Germany's Scholz calls for pragmatic approach to 'forever chemicals'
German Chancellor Olaf Scholz called for a pragmatic approach to toxic "forever chemicals" found in many household and everyday items during a visit to an Evonik site at the Marl Chemical Park on Mond...
Evonik - I Continue To Be Long Here
Evonik has shown growth and strong performance in 3Q and 4Q23, with a 19% increase in share price since the last article. The company is undergoing a strategic realignment and investing in future tech...
Evonik: Another Exit In A Low Margin Division
The company met its 2023 forecast despite a challenging environment, with positive performances in the Nutrition & Care division. Evonik confirmed its dividend per share thanks to a solid FCF and a su...
Evonik to Cut 6% of Workforce
Evonik said it would cut up to 2,000 jobs by 2026, expecting cost reductions of around €400 million, after its fourth-quarter underlying earnings came in slightly below consensus forecasts.
Evonik says recovery unlikely in 2024, plans 2,000 job cuts
German chemicals group Evonik Industries said on Monday it expected no signs of a recovery in 2024 and announced up to 2,000 job cuts worldwide by 2026 in a bid to cut costs.
Evonik: The Reversal Could Be Significant, 'Buy'
Evonik Industries' position is currently volatile and uncertain, but I'm not worried. The company's 3Q23 results were above expectations, with positive cash generation and a confirmed adjusted EBITDA ...
Germany's Economy Is in a Bad Slump. These 6 Stocks Could Rebound.
Look for companies that have been bearing the brunt of the pain to pull out stronger.
Evonik Industries AG (EVKIF) Q3 2023 Earnings Conference Call Transcript
Evonik Industries AG (EVKIF) Q3 2023 Earnings Conference Call Transcript
Evonik Industries AG (EVKIF) Q2 2023 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q2 2023 Earnings Conference Call August 10, 2023 5:00 AM ET Company Participants Tim Lange – Head-Investor Relations Christian Kullmann – Chief Executive Officer Mai...
Evonik: Building A Position For A Blockbuster 2023-2025 - Buy
Despite a downturn in the specialty chemicals sector, I remain positive about investment in Evonik Industries stock due to strong dividends, a BBB+ credit rating, and strong underlying fundamentals. T...
Evonik: A Slow Q1, But There Are Underlying Signs Of Improvement
Evonik is a relatively new position I've been establishing over the past few months, as the company has been troughing between €17-19/share for the native. The company reported 1Q23 results as I am wr...
Mr. Europe Says: 'Buy' 2 BBB+ Rated Companies With 5-7% Yield And Upside
I'll showcase two investments that I believe will outperform over the next few years - one of them reported 4Q22 on Friday and is in a nice daily decline over 6%. I'm heavily invested in both of these...
Evonik Is Significantly Undervalued With A Double-Digit Potential Upside
I've been loading up on Evonik for the past few months, showcasing these buys in Chat and in some general articles. Here I am doing more of a deep dive. Evonik has an interesting composition and an ap...
Evonik Industries AG (EVKIF) Q3 2022 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q3 2022 Earnings Conference Call November 8, 2022 5:00 AM ET Company Participants Christoph Finke - IR Christian Kullmann - CEO Ute Wolf - CFO Conference Call Partic...
Evonik: Earnings Defensiveness
Despite the ongoing energy price, the company left its 2022 outlook unchanged. Mare Evidence Lab's view versus Wall Street's main challenges.